Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. (Nasdaq: ESLA) is a clinical-stage biopharmaceutical company focused on immunotherapy that entered the public markets through a SPAC business combination with Acri Capital Acquisition Corporation, which completed its blank-check IPO in 2022. The September 2023 8-K filing reflects the company's reporting obligations as a newly public entity following the close of that de-SPAC transaction. Operating in the biotechnology and immunology sector, Estrella is developing therapeutic candidates targeting immune-mediated diseases and oncology indications. The company's post-merger status places it among a cohort of clinical-stage biotech SPACs navigating public market conditions in 2023. Sign up for SpacDesk to access the full data profile, SEC filing timeline, and deal analytics for ESLA.